Lung cancer research is taking on new challenges: knowledge of tumors' molecular diversity is opening new pathways to treatment.

Lung cancer treatment has undergone significant change in the past decade, leading to remarkable growth in the number and variety of therapeutic options. This shift reflects, in part, a significant refinement in the molecular categorization of lung cancer.

[1]  B. Kramer,et al.  Overdiagnosis in low-dose computed tomography screening for lung cancer. , 2014, JAMA internal medicine.

[2]  V. Moyer.  Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2014, Annals of Internal Medicine.

[3]  Richard Pazdur,et al.  Consensus Report of a Joint NCI Thoracic Malignancies Steering Committee: FDA Workshop on Strategies for Integrating Biomarkers into Clinical Development of New Therapies for Lung Cancer Leading to the Inception of “Master Protocols” in Lung Cancer , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  P. Forde,et al.  New Strategies in Lung Cancer: Translating Immunotherapy into Clinical Practice , 2014, Clinical Cancer Research.

[5]  W. North,et al.  Growth Impairment of Small-Cell Cancer by Targeting Pro-Vasopressin with MAG-1 Antibody , 2014, Front. Oncol..

[6]  K. O'Byrne,et al.  Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. , 2014 .

[7]  F. Detterbeck,et al.  Screening for Lung Cancer: Moving Into a New Era , 2014, Annals of Internal Medicine.

[8]  Michael Thomas,et al.  Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial. , 2014 .

[9]  A. Kossenkov,et al.  The peripheral immune response and lung cancer prognosis , 2012, Oncoimmunology.

[10]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[11]  P. Massion.  Biomarkers to the rescue in a lung nodule epidemic. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  William Pao,et al.  Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.

[13]  A. Copeland,et al.  Public attitudes about lung cancer: stigma, support, and predictors of support , 2014, Journal of multidisciplinary healthcare.

[14]  T. Yamanaka,et al.  Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Results of a Japanese randomized phase III trial. , 2014 .

[15]  P. Massion,et al.  Discovery of New Membrane-Associated Proteins Overexpressed in Small-Cell Lung Cancer , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  H. West.  Afatinib for advanced mutated NSCLC: New hope or new Coke? , 2014, The Journal of community and supportive oncology.

[17]  J. Brahmer.  Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer? , 2014, Seminars in oncology.

[18]  C. Schumann,et al.  A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). , 2014 .

[19]  Y. Hosomi,et al.  Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial. , 2014 .